company background image
ORMP

Oramed Pharmaceuticals NasdaqCM:ORMP Stock Report

Last Price

US$8.64

Market Cap

US$338.0m

7D

3.6%

1Y

-47.2%

Updated

08 Dec, 2022

Data

Company Financials +
ORMP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ORMP Stock Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.

Oramed Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oramed Pharmaceuticals
Historical stock prices
Current Share PriceUS$8.64
52 Week HighUS$17.51
52 Week LowUS$3.59
Beta2.32
1 Month Change30.51%
3 Month Change1.41%
1 Year Change-47.22%
3 Year Change62.41%
5 Year Change-0.69%
Change since IPO4,651.80%

Recent News & Updates

Recent updates

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12
The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Jan 08
Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Dec 04
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Shareholder Returns

ORMPUS PharmaceuticalsUS Market
7D3.6%-0.3%-2.8%
1Y-47.2%14.1%-19.6%

Return vs Industry: ORMP underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: ORMP underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is ORMP's price volatile compared to industry and market?
ORMP volatility
ORMP Average Weekly Movement10.3%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ORMP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ORMP's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aNadav Kidronhttps://www.oramed.com

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.

Oramed Pharmaceuticals Inc. Fundamentals Summary

How do Oramed Pharmaceuticals's earnings and revenue compare to its market cap?
ORMP fundamental statistics
Market CapUS$337.95m
Earnings (TTM)-US$46.28m
Revenue (TTM)US$2.71m

124.6x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORMP income statement (TTM)
RevenueUS$2.71m
Cost of RevenueUS$0
Gross ProfitUS$2.71m
Other ExpensesUS$48.99m
Earnings-US$46.28m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.18
Gross Margin100.00%
Net Profit Margin-1,706.42%
Debt/Equity Ratio0%

How did ORMP perform over the long term?

See historical performance and comparison